Serum urate lowering with allopurinol and kidney function in type 1 diabetes

Authors

Alessandro Doria, Harvard University
Janet B. McGill, Washington University School of Medicine in St. Louis
et al.

Journal

New England Journal of Medicine

Publication Date

2020

Volume

382

Issue

26

First Page

2493

Last Page

2503

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1916624

Rights and Permissions

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M; PERL Study Group. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 Jun 25;382(26):2493-2503. doi: 10.1056/NEJMoa1916624. Copyright © 2020 Massachusetts Medical Society. All rights reserved.

Recommended Citation

Doria, Alessandro; McGill, Janet B.; and al., et, "Serum urate lowering with allopurinol and kidney function in type 1 diabetes." New England Journal of Medicine. 382, 26. 2493 - 2503. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9513